Treatment-inhaled tPA

Phase 2Small molecule

UUniversity of Michigan

Treatment-inhaled tPA is one of 32 small molecule programs targeting Bronchitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchitisActive, not recruiting

BronchitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Bronchitis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

1 2

Zyvox

Pfizer

Approved

1 3

Primaxin

Pfizer

Approved

1 4

Singulair

AstraZeneca

Approved

1 5

Coly-Mycin M

PParkedale

Approved

1 6

Singulair

OOrganon and Co

Approved

1 7

Rocephin

CConrado Roberto Hoffmann Filho

Approved

1 8

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Pulmicort

Inhaled Budesonide

UUniversity of British Columbia

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bronchitis1 trial

Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis

Completed·UUniversity of Michigan·Phase 2·NCT02315898·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Treatment-inhaled tPA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Treatment-inhaled tPA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Treatment-inhaled tPA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Michigan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Michigan

Treatment-inhaled tPA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bronchitis1 trial

References

Drug Info

Quick Facts

Related News